Few medicines carry as much evidence — or as much anxiety — as statins. They are the best-studied drugs in cardiovascular medicine, with decades of large trials behind them, yet many people approach them with real hesitation. This guide is not here to tell you whether to take a statin. It's here to explain, calmly and accurately, what they do and how to think about them — so that the conversation with your own doctor is an informed one.
What do statins do?
Statins lower the number of atherogenic (ApoB-containing) particles in your blood — chiefly LDL — by helping the liver clear them faster. Across decades of trials, that translates into fewer heart attacks and strokes. Whether a statin is right for a given person, and at what intensity, is a clinical decision that depends on their overall risk — one made with a physician, not from an article.
How statins work
Statins block an enzyme in the liver called HMG-CoA reductase, a key step in cholesterol production. In response, liver cells display more LDL receptors on their surface, which pull LDL particles out of the bloodstream more efficiently. The result is a lower circulating ApoB and LDL-C — fewer of the particles that drive atherosclerosis.
This is why statins are described as treating the cause of atherosclerotic risk rather than a symptom: they reduce the particle burden that physically builds arterial plaque over time.
Who statins are considered for
This is a decision for a clinician, based on a person's overall cardiovascular risk — not something to self-determine. In general, physicians consider statin therapy for people such as:
- Those with established cardiovascular disease (a prior heart attack, stroke, or known arterial disease).
- Those at high or very-high estimated risk — see how risk category is determined.
- People with familial hypercholesterolemia or markedly elevated LDL-C / ApoB.
- Many people with diabetes, depending on age and other factors.
Being in one of these groups doesn't mean a statin is automatically the answer — it means it's a reasonable conversation to have. The decision weighs the size of the expected benefit against the individual's preferences and circumstances.
Intensity, not just "on or off"
Statins are often grouped by how much they lower LDL-C — broadly moderate-intensity and high-intensity. Higher-intensity regimens lower ApoB and LDL-C more, and are typically reserved for higher-risk situations. The specific agent and dose are matched to the person's risk, targets, and tolerability by their physician; there is no single "right" statin or dose that applies to everyone.
The target behind the dose: the point of a statin isn't a number on the bottle — it's reaching an ApoB / LDL target appropriate for your risk. That's why two people can be on very different regimens and both be treated correctly.
What the evidence shows
Statins are supported by one of the largest bodies of randomized evidence in all of medicine. Pooled analyses of many trials — most notably by the Cholesterol Treatment Trialists' (CTT) Collaboration — show a consistent finding: lowering LDL-C with a statin reduces the risk of major cardiovascular events, and the benefit is proportional to how much the particle burden falls and how long it stays low. The relationship holds across a wide range of starting risk levels.
This is the same principle that runs through the rest of cardiovascular prevention: it's the cumulative exposure to atherogenic particles that drives disease, so reducing that exposure — earlier and for longer — is what changes outcomes.
Side effects: an honest, calm picture
Concern about side effects is the single most common reason people hesitate, so it deserves a straight answer rather than either dismissal or alarm.
Muscle symptoms
Muscle aches are the most talked-about statin concern. The reality from blinded trials is reassuring: the large majority of people tolerate statins well, and in carefully designed studies, most muscle symptoms occurred just as often on placebo as on the active drug — a pattern known as the nocebo effect. Genuine statin-associated muscle symptoms do occur in a minority, and they are almost always manageable — by adjusting the dose, switching agents, or other strategies your physician can offer. Serious muscle injury is rare.
Blood sugar and other effects
Statins are associated with a small increase in the risk of developing type 2 diabetes, mostly in people already close to that threshold. Importantly, across the evidence, the cardiovascular benefit for those who need a statin outweighs this small risk. Effects on the liver are usually minor; your physician monitors what needs monitoring.
Important: if you're already taking a statin and experience symptoms, the safest step is to speak with your physician before changing anything — not to stop on your own. Stopping a needed medication carries its own risk, and most side-effect problems have a solution that keeps you protected.
Statins and Lp(a): clearing up a common worry
You may read that statins can slightly raise Lp(a). This is true — but it is not a reason to avoid statins. The effect on Lp(a) is small, while the reduction in ApoB and overall cardiovascular risk is large and well-proven. For someone with high Lp(a), controlling every other risk factor — which is exactly what a statin does by lowering ApoB — is a cornerstone of management, precisely because Lp(a) itself can't yet be lowered with an approved drug.
If a statin isn't enough — or isn't tolerated
When a statin alone doesn't bring ApoB and LDL-C to target, or when someone genuinely can't tolerate one, other options exist. Additional classes of lipid-lowering therapy — such as ezetimibe, PCSK9 inhibitors, and bempedoic acid — can be added or substituted. Which, if any, is appropriate is a decision for you and your physician, guided by your targets and your full risk picture. CardioIQ does not recommend specific drugs; that judgement belongs in the clinic.
They treat the cause
Statins lower the ApoB particle burden that drives plaque — not just a lab number.
Strongest evidence base
Decades of large randomized trials link statin LDL-lowering to fewer events.
Mostly well tolerated
Blinded trials show most muscle symptoms occur as often on placebo — manageable when real.
Never stop solo
If side effects arise, your physician has solutions — changing things alone carries risk.
Questions to bring to your doctor
- "Given my risk category and my ApoB, would you consider a statin — and what would it be aiming to achieve?"
- "What ApoB or LDL target are we treating toward, and how will we check that I've reached it?"
- "If I get muscle symptoms, what are our options before stopping?"
- "My Lp(a) is high — how does that change your thinking about lowering everything else?"
Common Questions
The evidence strongly supports that, in people for whom they're indicated, lowering LDL-C with a statin reduces the risk of heart attacks and strokes — with benefit proportional to how much the particle burden falls. Whether that benefit applies meaningfully to a given person depends on their baseline risk, which is a clinical judgement.
Because atherosclerotic risk relates to long-term particle exposure, statins are usually intended as a long-term therapy rather than a short course. That said, the plan is individual and is something to revisit with your physician over time, not a fixed sentence.
Lifestyle genuinely helps and is worthwhile for everyone — but how far it moves ApoB and LDL-C varies a lot from person to person, and for some (especially those with familial hypercholesterolemia or high baseline risk) it isn't sufficient on its own. Whether lifestyle alone is a reasonable strategy for you is a conversation to have with your doctor, ideally with your numbers in front of you.
Statins are widely used across a broad range of ages, and the decision in older adults weighs expected benefit against overall health and preferences — exactly the kind of individualized judgement a physician is there to make. Age alone neither rules a statin in nor out.
Know Your Numbers Before the Conversation
CardioIQ reads your ApoB, LDL, Lp(a), and full risk profile against longevity-optimal targets — so you walk into that discussion with your physician already understanding where you stand.
See how CardioIQ reads your panel View a sample report →Important Medical Notice. This article is educational only. It is not medical advice, not a recommendation to start, stop, or change any medication, and not a substitute for care from a qualified clinician. CardioIQ does not prescribe treatment. Decisions about statins or any other therapy — including dose and duration — must be made with your physician, who knows your full history. If you are taking a statin and have concerns, speak with your doctor before making any change.
References
- Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy: meta-analyses of randomized trials. The Lancet (multiple analyses).
- 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. doi:10.1093/eurheartj/ehz455
- 2018 AHA/ACC/Multisociety Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. doi:10.1016/j.jacc.2018.11.003